STOCK TITAN

Treace Medical Concepts, Inc. - TMCI STOCK NEWS

Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.

Treace Medical Concepts, Inc. (TMCI) is a leader in 3D bunion correction and foot/ankle surgical solutions, delivering innovative technologies like the Lapiplasty system. This page provides timely updates on TMCI’s advancements in orthopedic medical devices, financial milestones, and clinical research.

Access press releases covering product launches, regulatory approvals, and partnerships that shape surgical practices. Investors will find earnings reports and strategic updates, while medical professionals can track procedural innovations and training opportunities.

Our curated news collection ensures you stay informed about TMCI’s contributions to reproducible surgical outcomes and cost-effective patient care. Content is verified for accuracy and relevance, offering a neutral perspective on company developments.

Bookmark this page for streamlined access to TMCI’s latest achievements in addressing complex deformities through evidence-based solutions. Regularly updated to reflect the company’s commitment to advancing orthopedic care.

Rhea-AI Summary

Treace Medical Concepts, Inc. (Nasdaq: TMCI) announced a new five-year $150 million loan arrangement with MidCap Financial. This includes up to $120 million in term loans and a $30 million revolving credit facility. The term loan refinances their existing $30 million debt. CEO John T. Treace emphasized that this non-dilutive financing strengthens the company's balance sheet, providing financial flexibility for growth in the bunion surgery market. The company reported cash and liquidity access of approximately $220 million post-refinancing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Treace Medical Concepts (NasdaqGS: TMCI) announced it will release its financial results for the first quarter of 2022 on May 5, 2022, after market close. A conference call will be held at 4:30 p.m. ET to discuss these results. The company specializes in innovative surgical solutions for bunion deformities, notably the patented Lapiplasty® 3D Bunion Correction™ system. This system aims to address the root causes of bunions and facilitate recovery. The event will be accessible via a conference call and webcast on Treace's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags
conferences earnings
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) has filed a lawsuit against Fusion Orthopedics in the U.S. District Court for Arizona, claiming infringement on several patents related to its Lapiplasty® 3D Bunion Correction™ system. The lawsuit includes allegations of copyright infringement, trademark rights violation, and unfair competition, seeking both injunctive relief and damages. CEO John T. Treace emphasized the importance of their intellectual property, which supports continued innovation in bunion treatment, benefiting thousands of patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
none
Rhea-AI Summary

Treace Medical Concepts (TMCI) reported strong financial results for Q4 and full year 2021. Q4 revenue hit $33.4 million, a 39% year-over-year increase, with full year revenue reaching $94.4 million, up 65%. Gross margins improved to 81.1% in Q4, reflecting higher sales volume and pricing. The company made strategic investments in sales and marketing, contributing to a 58% direct sales channel revenue in Q4. Despite these gains, TMCI reported a net loss of ($6.6) million for Q4 and ($20.7) million for 2021. The outlook for 2022 anticipates revenue of $125 million to $130 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) has presented the latest interim analysis from the ALIGN3D clinical study at the 2022 ACFAS Annual Scientific Conference. The analysis included data from 160 participants, demonstrating a return to weight-bearing in 8.5 days and significant improvements in pain reduction and quality of life after 12 and 24 months following the Lapiplasty procedure. Notably, the recurrence rates were low at 0.9% and 0.0% at 12 and 24 months, respectively. CEO John T. Treace expressed commitment to advancing clinical evidence supporting their solutions for bunion patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
none
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) announces new product innovations at the 2022 ACFAS Annual Scientific Conference in Austin, Texas, from February 24-27. Key highlights include:

  • Lapiplasty® 3-n-1™ Guide: A precision instrument designed to enhance the efficiency of the bunion correction procedure.
  • Adductoplasty™ Midfoot Correction System: Expansion of the system to improve efficiency and treat various midfoot conditions.
  • Lapiplasty® S4A Anatomic Plating System: Next-generation titanium plates for improved surgical outcomes.
  • SpeedRelease™ and TriTome™ Instruments: New cutting tools for enhanced surgical release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.72%
Tags
none
Rhea-AI Summary

Treace Medical Concepts (NasdaqGS: TMCI) will announce its financial results for Q4 and the full year of 2021 on March 3, 2022, after market close. A conference call is scheduled for 4:30 p.m. ET, where management will discuss these results. Interested investors can join the call by dialing (888) 708-0264 domestically or (720) 405-2122 internationally, using Conference ID: 6356356. Treace is known for the Lapiplasty® 3D Bunion Correction™ System and recently introduced the Adductoplasty™ Midfoot Correction System to enhance treatment options for bunion deformities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.16%
Tags
conferences earnings
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) announced the podium presentation of interim analysis data from its ALIGN3D™ clinical study at the ACFAS Annual Scientific Conference from February 24-27, 2022, in Austin, Texas. The presentation, led by Dr. George Tye Liu, will focus on a five-year multicenter study evaluating outcomes of the Lapiplasty® 3D Bunion Correction™. The study, involving 173 patients, aims to assess the effectiveness of correcting hallux valgus deformity with a focus on various clinical outcomes. Final follow-up for primary endpoints is expected in the first half of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags
none
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) announced the granting of U.S. Patent No. 11,213,333 for its innovative bunion correction technology. This patent enhances Treace's robust patent portfolio, which includes over 40 granted patents and more than 50 pending applications globally. The patent covers a technique utilizing a bone preparation and positioning guide for bunion correction, further solidifying Treace's commitment to surgical innovation. CEO John T. Treace emphasized the significance of this patent in advancing treatment options for bunion patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
none
Rhea-AI Summary

Treace Medical Concepts (TMCI) announced preliminary unaudited revenue results for Q4 and full year 2021, projecting revenues between $33.1 million to $33.4 million for Q4 and $94.1 million to $94.4 million for the year, marking a growth of 37% to 39% and 64% to 65% year-over-year, respectively. The company highlights a 53% to 54% sequential revenue increase from Q3 2021. CEO John T. Treace expressed confidence in their market position and the effectiveness of their Lapiplasty® System. Financial guidance for 2022 is expected during their upcoming earnings call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.86%
Tags
none

FAQ

What is the current stock price of Treace Medical Concepts (TMCI)?

The current stock price of Treace Medical Concepts (TMCI) is $7.05 as of April 29, 2025.

What is the market cap of Treace Medical Concepts (TMCI)?

The market cap of Treace Medical Concepts (TMCI) is approximately 401.8M.
Treace Medical Concepts, Inc.

Nasdaq:TMCI

TMCI Rankings

TMCI Stock Data

401.76M
47.08M
26.04%
60.61%
4.36%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
PONTE VEDRA